Policy / Pricing Average Drug Fills and Average Gross Drug Costs Per Medicare Part D Enrollee pharminent April 30, 2026
Regulatory UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy pharminent April 30, 2026
Commercial Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch pharminent April 30, 2026
Commercial Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth pharminent April 30, 2026
Pipeline AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio pharminent April 30, 2026
Clinical Data GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints pharminent April 30, 2026
Clinical Data Survodutide delivers 16.6% weight loss in major phase 3 obesity trial pharminent April 30, 2026
Commercial Pfizer protects $6.4bn heart disease blockbuster from generics, for now pharminent April 29, 2026
Other FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech pharminent April 29, 2026
Market Access Flash Brief: PBM Reform Collides with MFN Pricing as Midterm Politics Reshape the Drug Pricing Landscape pharminent April 29, 2026
Commercial Pfizer settles with generic drugmakers to protect blockbuster drug until 2031 pharminent April 29, 2026
Regulatory AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions pharminent April 29, 2026
Commercial Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’ pharminent April 29, 2026
Manufacturing The strategic investments expanding CDMO capabilities for HPAPIs and ADCs pharminent April 29, 2026
Commercial Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies pharminent April 29, 2026
Commercial Pfizer deals extend patent life for a top-selling rare disease drug pharminent April 28, 2026
Regulatory Intellia Initiates Rolling BLA Submission for In Vivo CRISPR Therapy in Hereditary Angioedema pharminent April 28, 2026
M&A / Deals AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B pharminent April 28, 2026
Clinical Data Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3 pharminent April 28, 2026
Clinical Data AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer pharminent April 28, 2026
M&A / Deals Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’ pharminent April 28, 2026
M&A / Deals Coultreon banks $125M to support testing of former Galapagos immune drug pharminent April 28, 2026
M&A / Deals Merck KGaA and Remepy join forces to develop combo drug-digital therapies pharminent April 28, 2026
